Free Cash Flow Chart

Historical Free Cash Flow Data

View and export this data back to 2018. Start Trial.
Date Value
September 30, 2026 -3.399M
June 30, 2026 10.06M
March 31, 2026 3.745M
December 31, 2025 -50.60M
September 30, 2025 -121.04M
June 30, 2025 -133.96M
March 31, 2025 -109.57M
December 31, 2024 -109.45M
September 30, 2024 -102.53M
June 30, 2024 -104.76M
March 31, 2024 -117.96M
December 31, 2023 -125.54M
September 30, 2023
June 30, 2023
March 31, 2023
September 30, 2022 -98.84M
Date Value
June 30, 2022 -97.19M
March 31, 2022 -82.22M
December 31, 2021 -65.75M
September 30, 2021 -100.00M
June 30, 2021 -99.89M
March 31, 2021 -88.85M
December 31, 2020 -100.99M
September 30, 2020 -87.91M
June 30, 2020 -79.37M
March 31, 2020 -86.41M
December 31, 2019 11.06M
September 30, 2019 17.43M
June 30, 2019 25.81M
March 31, 2019 29.51M
December 31, 2018 -70.15M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Xencor, Inc. -176.45M
UroGen Pharma Ltd. -136.57M
Ironwood Pharmaceuticals, Inc. 205.37M
Viking Therapeutics, Inc. -462.63M
IDEAYA Biosciences, Inc. -349.80M